Axel S. Merseburger(@amerseburger) 's Twitter Profileg
Axel S. Merseburger

@amerseburger

Professor of Urology, Chairman Department of Urology, EiC "Aktuelle Urologie", Editor World Journal of Urology. Chairman EUSP, EAU-Board Member

ID:5402392

linkhttp://www.urologie.uni-luebeck.de calendar_today22-04-2007 14:35:27

3,1K Tweets

4,3K Followers

1,0K Following

Axel S. Merseburger(@amerseburger) 's Twitter Profile Photo

Huge thank you to Prof. Tomita and Prof. Eto and teams for unmatched hospitality at in Japan. Truly like the motto: „Beyond Boundaries“. Japan Urology at its best! Looking forward to to JUA2025. Kevin Koo 新潟大学泌尿器科学教室(Niigata Urology)
@uroweb Juan Luis Vásquez OncoAlert

Huge thank you to Prof. Tomita and Prof. Eto and teams for unmatched hospitality at #JUA2024 in #Yokohama Japan. Truly like the motto: „Beyond Boundaries“. Japan Urology at its best! Looking forward to to JUA2025. @kvnkoo @NiigataUrology @uroweb @JLVasquez82 @OncoAlert
account_circle
Advanced Prostate Cancer Consensus Conference(@APCCC_Lugano) 's Twitter Profile Photo

Good morning family! 🌅

It's Day 2, and we're bursting for another day of innovative discussions and groundbreaking insights. Are you as excited as we are?

Today, we kick off with the eagerly awaited extra session on the groundbreaking IRONMAN project, brought to you…

account_circle
Markus Eckstein(@Markuseckstein3) 's Twitter Profile Photo

We are happy to share our new study published today Journal of Clinical Oncology (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer.
With a huge contribution of our multinational team we uncovered…

We are happy to share our new study published today @JCO_ASCO (👉 ascopubs.org/doi/10.1200/JC…) on the role of NECTIN4 amplifications to predict responses to Enfortumab Vedotin treatment in metastatic urothelial cancer. With a huge contribution of our multinational team we uncovered…
account_circle
Niklas Klümper(@niklas_kluemper) 's Twitter Profile Photo

Very happy to share our study published Journal of Clinical Oncology ! ascopubs.org/doi/full/10.12…

➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4…

Very happy to share our study published @JCO_ASCO ! ascopubs.org/doi/full/10.12… ➡️Patients with mUC with NECTIN4 amplifications (occurring in app. 25%) show remarkable responses to single-agent EV, with a 96% objective response rate compared to 32% in non-amplified cases. NECTIN4…
account_circle
Yüksel Ürün(@DrYukselUrun) 's Twitter Profile Photo

Everyday clinical question to Nick James
⭕️Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) are candidates for a combination of ADT, docetaxel, and AR pathway inhibitors?
⭕️The selection for this potent triplet systemic therapy requires careful…

Everyday clinical question to @Prof_Nick_James ⭕️Which patients with metastatic hormone-sensitive prostate cancer (mHSPC) are candidates for a combination of ADT, docetaxel, and AR pathway inhibitors? ⭕️The selection for this potent triplet systemic therapy requires careful…
account_circle
Dra. María Natalia Gandur Quiroga(@nataliagandur) 's Twitter Profile Photo

🚀 Session 1: High-risk & locally advanced prostate cancer. Chairs Neha Vapiwala & Neal Shore will explore the relevance of digital rectal exams in the era of MRI and next-gen imaging. Join the conversation! 💡
OncoAlert Advanced Prostate Cancer Consensus Conference
🔍 Insightful talk by…

🚀 #APCCC24 Session 1: High-risk & locally advanced prostate cancer. Chairs Neha Vapiwala & Neal Shore will explore the relevance of digital rectal exams in the era of MRI and next-gen imaging. Join the conversation! 💡 @OncoAlert @APCCC_Lugano 🔍 Insightful talk by…
account_circle
Dra. María Natalia Gandur Quiroga(@nataliagandur) 's Twitter Profile Photo

🌟 kicks off TODAY, April 25th! Don’t miss the APCCC 2024 opening session featuring silke gillessen and aurelius omlin
OncoAlert  Advanced Prostate Cancer Consensus Conference 
🔍 David Matheson will delve into what's important from a patient's perspective. Connect with us and leading oncology experts!…

🌟 #APCCC24 kicks off TODAY, April 25th! Don’t miss the APCCC 2024 opening session featuring @Silke_Gillessen and @AOmlin @OncoAlert  @APCCC_Lugano  🔍 David Matheson will delve into what's important from a patient's perspective. Connect with us and leading oncology experts!…
account_circle
OncoAlert(@OncoAlert) 's Twitter Profile Photo

Siamo arrivati a Lugano🇨🇭
And what an office view ⛵️

is coming to us tomorrow and OncoAlert 🚨is beyond proud to be working with Advanced Prostate Cancer Consensus Conference in the coverage of this great conference.

Look forward to some amazing discussions and very excited to be doing that in…

Siamo arrivati a Lugano🇨🇭 And what an office view ⛵️ #APCCC24 is coming to us tomorrow and @OncoAlert 🚨is beyond proud to be working with @APCCC_Lugano in the coverage of this great conference. Look forward to some amazing discussions and very excited to be doing that in…
account_circle
Advanced Prostate Cancer Consensus Conference(@APCCC_Lugano) 's Twitter Profile Photo

We can't wait for tomorrow's Translational Prostate Cancer Symposium, the prelude to the eagerly awaited !

Join us on April 24th in Lugano.

🔬 Session Breakdown:
Welcome And Opening Remarks by Silke Gillessen silke gillessen and Jean-Philippe Theurillat Jean-Philippe Theurillat.…

account_circle
Markus Eckstein(@Markuseckstein3) 's Twitter Profile Photo

Cannot agree more ! ADCs need their target to bind -> no target no action.

It is an exciting time for translational research in this field. Pathologists need to be involved as we will need to test for many indications soon likely!

oncology!

Markus Eckstein Paolo Tarantino

account_circle
Advanced Prostate Cancer Consensus Conference(@APCCC_Lugano) 's Twitter Profile Photo

With less than a week until begins, we’re highlighting again the crucial sessions on systemic therapy side effects and metastatic CRPC management.

Whether you join us in the city of Lugano🇨🇭or tune in virtually, these discussions are pivotal for anyone interested in…

account_circle